News

The results from the EXPEDITION (including FLIGHT 1, 2 and 3 studies) and GEM clinical trial programs met their primary and secondary endpoints. COPD symptoms can negatively impact

RYTARY is an extended-release oral capsule formulation of carbidopa-levodopa. It is not indicated for use in patients using nonselective monoamine oxidase inhibitors (MAO) inhibitors. The drug contains immediate

The new registration trial follows positive data from the company’s completed Phase Ib/IIa VERTICAL trial as well as the ongoing long-term Extension Study. The randomized, open-label, Phase III

As part of the deal, Nuo will receive an upfront payment from Rohto in return for an exclusive license and the right to develop and commercialize Aurix in

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound. It has also secured orphan designation in multiple myeloma from the European Medicines Agency (EMA).

Savaysa is an oral, once-daily selective factor Xa-inhibitor developed to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). Daiichi Sankyo

The antibiotic compound has been discovered in a screen against NovoBiotic’s extract library generated from previously uncultured microbes. NovoBiotic president Dr Dallas Hughes said: "The discovery of teixobactin

The trial, which is designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat, will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300

Under the deal, Tetragenetics will use its ion channel production technology, SionX, to produce about five ion channel antigens for MedImmune’s antibody drug discovery programs. The company said